CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Gold Standard Diagnostics’ new Line Immunoassay technology for Lyme confirmation testing gives clinical laboratories an FDA-cleared option for serological confirmation testing for Lyme disease according to the CDC-recommended two-step process.
Both the IgG and IgM line blots are equivalent to traditional Western blot technology but offer advancements in usability and objectivity through use of Line Immunoassay technology. GSD’s LIA test strips are more sensitive and specific, provide consistent results and automation options, and come in large lot sizes.
The line blots are easy to handle and read. Included are clinically significant antigens. Ten IgG antigens match CDC requirements for testing for general infection and determination of the stage of infection. All three IgM proteins are included for early and disseminated Lyme disease diagnosis.
Strips are affixed in a booklet of durable materials. The unique numbering system makes working with GSD’s Lyme line blots simple, regardless of test volume.
Gold Standard Diagnostics, 530-759-8000
Gold Standard Diagnostics, 530-759-8000